Zobrazeno 1 - 10
of 53
pro vyhledávání: '"Sulabha Ramachandran"'
Autor:
Murray B Urowitz, Robert L Ohsfeldt, Ronald C Wielage, Yumi Asukai, Sulabha Ramachandran, John J Dever, Mehdi Zakerifar, Ashish V Joshi
Publikováno v:
Lupus Science and Medicine, Vol 7, Iss 1 (2020)
Objective Long-term extension (LTE) studies of belimumab in SLE do not include a comparator arm, preventing comparisons between belimumab plus standard therapy and standard therapy alone for organ damage accrual. Propensity score matching can be used
Externí odkaz:
https://doaj.org/article/dc2744ed51b543499c22bb195b10560a
Publikováno v:
Journal of Health Economics and Outcomes Research, Vol 5, Iss 2 (2018)
**Background:** Current knowledge of the disease burden of primary Sjögren’s syndrome (pSS) is limited. **Objectives:** The primary objective of this study was to describe the demographic and clinical characteristics of patients with pSS. The sec
Externí odkaz:
https://doaj.org/article/bc3b9281b7864bc0be5e551cf4a4d71c
Publikováno v:
Preventing Chronic Disease, Vol 2, Iss 1 (2005)
Introduction Community indicators are used to measure and monitor factors that affect the well-being of a community or region. Community indicators can be used to assess nutrition. Evaluating nutrition in communities along the Arizona-Mexico border i
Externí odkaz:
https://doaj.org/article/3f10dd198dde4235a2e3813e9452e056
Publikováno v:
Journal of Health Economics and Outcomes Research
**Background:** Current knowledge of the disease burden of primary Sjogren’s syndrome (pSS) is limited. **Objectives:** The primary objective of this study was to describe the demographic and clinical characteristics of patients with pSS. The secon
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f01cfe31e68d07e457f2e9b50d3a3fa0
https://pubmed.ncbi.nlm.nih.gov/35620779
https://pubmed.ncbi.nlm.nih.gov/35620779
Autor:
Y Asukai, Robert L. Ohsfeldt, Sulabha Ramachandran, Ronald C Wielage, KA Kelton, Murray B. Urowitz
Publikováno v:
Annals of the Rheumatic Diseases
ObjectivesThe study (206347) compared organ damage progression in patients with systemic lupus erythematosus (SLE) who received belimumab in the BLISS long-term extension (LTE) study with propensity score (PS)-matched patients treated with standard o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::61e6e8f193540eab744848436d10c5b2
https://doi.org/10.1136/annrheumdis-2018-214043
https://doi.org/10.1136/annrheumdis-2018-214043
Autor:
Ebony Dashiell-Aje, Sulabha Ramachandran, Jane DeVries, Gale Harding, Pamela Berry, Katie Pascoe
Publikováno v:
The Patient
Objective This study assessed patient experiences of using an autoinjector device to self-administer subcutaneous belimumab for the treatment of systemic lupus erythematosus (SLE). Satisfaction, ease and convenience of use, and confidence with the de
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::da7f6c7303794d396bdd40ec33ccc23f
http://europepmc.org/articles/PMC5766732
http://europepmc.org/articles/PMC5766732
Publikováno v:
The Journal of Rheumatology. 43:1897-1903
Objective.Implications of inadequate gout control were assessed through health-related quality of life (HRQOL) and work productivity of patients with gout adequately controlled while taking conventional urate-lowering therapy (ULT) for ≥ 3 months v
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5a9a43f7ffa5a1343746c231e9fc24de
https://doi.org/10.3899/jrheum.151199
https://doi.org/10.3899/jrheum.151199
Autor:
John J Dever, Ashish V Joshi, Mehdi Zakerifar, Murray B. Urowitz, Sulabha Ramachandran, Robert L. Ohsfeldt, Ronald C Wielage, Y Asukai
Publikováno v:
Lupus Science & Medicine
Lupus Science and Medicine, Vol 7, Iss 1 (2020)
Lupus Science and Medicine, Vol 7, Iss 1 (2020)
ObjectiveLong-term extension (LTE) studies of belimumab in SLE do not include a comparator arm, preventing comparisons between belimumab plus standard therapy and standard therapy alone for organ damage accrual. Propensity score matching can be used
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::881ac79cb8f4efe8a9fbb071a058cddb
https://doi.org/10.1136/lupus-2020-000412
https://doi.org/10.1136/lupus-2020-000412
Autor:
M Urowitz, M. Zakerifar, Robert L. Ohsfeldt, Sulabha Ramachandran, Ashish V Joshi, J.J. Dever, Y Asukai, Ronald C Wielage
Publikováno v:
FRIDAY, 15 JUNE 2018.
Background A pooled analysis of the open-label BLISS LTE studies (BEL112233/BEL112234) reported low levels of organ damage accrual (measured by Systemic Lupus International Collaborating Clinics [SLICC]/American College of Rheumatology Damage Index [
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::aa84e54d575f486d8ec707d6a1e14037
https://doi.org/10.1136/annrheumdis-2018-eular.3319
https://doi.org/10.1136/annrheumdis-2018-eular.3319
Autor:
Sulabha Ramachandran, Daniel Parks, Rafael Alfonso-Cristancho, David M. Roth, Milena Kurtinecz
Publikováno v:
Journal of comparative effectiveness research. 7(6)
Aim: To compare the efficacy of intravenous (IV) and subcutaneous (SC) belimumab plus standard therapy in patients with active, autoantibody-positive systemic lupus erythematosus and high disease activity (HDA). Patients & methods: An indirect treatm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f60ad5ce10887b352da447c89546f905
https://pubmed.ncbi.nlm.nih.gov/29692179
https://pubmed.ncbi.nlm.nih.gov/29692179